Navigation Links
Biodel Reports Second Quarter Fiscal Year 2011 Financial Results
Date:5/5/2011

company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.Biodel Inc.
(A Development Stage Company)
[Condensed] Balance Sheets
(in thousands, except share and per share amounts)September 30,March 31,20102011(unaudited)ASSETSCurrent:Cash and cash equivalents$

22,922$

17,559Restricted cash15060Marketable securities, available for sale6,001—Taxes receivable116116Other receivables1150Prepaid and other assets365772Total current assets29,56518,557Property and equipment, net2,9982,564Intellectual property, net5351LT other assets—8Total assets$

32,616$

21,180LIABILITIES AND STOCKHOLDERS' EQUITYCurrent:Accounts payable$

1,989$

231Accrued expenses:Clinical trial expenses1,362806Payroll and related357671Accounting and legal fees300214Severance—910Other334181Income taxes payable4550Total current liabilities4,3873,063 Common stock warrant liability4,1691,634Other long term liabilities—484Total liabilities$

8,556$

5,181CommitmentsStockholders' equity:Preferred stock, $.01 par value; 50,000,000 shares authorized, none outstandingCommon stock, $.01 par value; 100,000,000 shares authorized; 26,399,764 and 26,496,131 issued and outstanding264265Additional paid-in capital188,549191,239Accumulated other comprehensive income1—Deficit accumulated during the development stage(164,754)(175,505)Total stockholders' equity24,06015,999Total liabilities and stockholders' equity$

32,616$

21,180Biodel Inc.
(A Development Stage Company)Condensed Statements of Operations(in thousands, except share and per share amounts)(unaudited)December 3,2003Three Months EndedSix Months Ended(inception) toMarch 31,March 31,March 31,20102011201020112011Revenue$

—$

—$

—$

—$

—Operating expenses:Research and development
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Biodel to Report Second Quarter Fiscal Year 2011 Financial Results on May 5, 2011
2. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
3. Biodel Announces Appointment of Dr. Brian J.G. Pereira as Board Chairman; Dr. Charles A. Sanders to Remain on Board
4. Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012
5. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
6. Biodel Inc. to Present at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011
7. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
8. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
9. Biodel Reports First Quarter Fiscal Year 2011 Financial Results
10. Biodel to Report First Quarter Fiscal Year 2011 Financial Results on February 3, 2011
11. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... announced a strategic collaboration focused on the development, ... active pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s ... their expertise in developing and manufacturing controlled substance ... to tech transfer processes into these facilities. The ...
(Date:8/31/2015)... August 31, 2015 Premune ... into an exclusive licensing agreement for Redonyl ® ... $300 million USD veterinary dermatology market, is a nutritional ... support healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the ...
(Date:8/31/2015)... Aug. 31, 2015  QT Vascular Ltd., together with its ... with its subsidiaries, the "Group"), a global company ... advanced therapeutic solutions for the minimally invasive treatment ... of the below-the-knee ("BTK") cohort of patients in ... presented on August 15, 2015 at the 5th ...
Breaking Medicine Technology:AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4
... , April 29, 2010 Albireo today,announced ... recent study,assessing the safety, tolerability and efficacy of A3309 ... compound for,the treatment of irritable bowel syndrome with constipation ... during the 2010,Digestive Disease Week (DDW) annual meeting being ...
... SALT LAKE CITY , April 28 Sonic Innovations, ... Administration (VA), is conducting ongoing training events for government clinicians.  The company ... in San Diego, California and April 25 through ... for May 3 through 5 in Salt Lake City, ...
Cached Medicine Technology:Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 2Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 3Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 4Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 5Sonic Innovations Conducts National Training Events for Government Clinicians 2Sonic Innovations Conducts National Training Events for Government Clinicians 3
(Date:9/1/2015)... , ... September 01, 2015 , ... Routines… every family ... routines can help make things easier for parents, caregivers and children too. Here are ... transitions both big and small become more fluid. When a routine is implemented into ...
(Date:9/1/2015)... ... 01, 2015 , ... The premier online medical education company ... leader in podiatric, surgical and wound care conferences . The Residency Education ... speakers at the podium and across the table during hands-on surgical and advanced ...
(Date:8/31/2015)... ... 31, 2015 , ... Jvion, the Atlanta-based leader in predictive ... focused on helping hospital perform under the Center for Medicare & Medicaid Services’ ... based on performance across four domains related to care quality. To receive a ...
(Date:8/31/2015)... Beach, FL (PRWEB) , ... August 31, 2015 , ... ... of companies – has teamed up with fellow South Walton property management ... on eliminating extreme poverty in remote parts of the world. The two companies will ...
(Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... The ... that Firm Partner William Scott has been nominated by his peers to earn a ... less than five percent of attorneys in the state of Illinois. The nomination process ...
Breaking Medicine News(10 mins):Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2
... As part of its ongoing commitment to keeping ... recognized leader in innovative healthcare administration for over 20 ... new full-service pharmacy benefit management (PBM) program, MagnaCareRx. ... pharmacy benefit management. With costs rising, plan sponsors can,t ...
... findings , TUESDAY, July 7 (HealthDay News) -- Parents ... that show a reduced-dose schedule for the pneumococcal vaccine ... The current recommended dose schedule for 7-valent pneumococcal conjugate ... age of 6 months, followed by a booster vaccination ...
... linked in studies to lower incidence of type 2 diabetes ... of a protein created by fat cells are associated with ... protein, adiponectin, appears to have anti-inflammatory and insulin-sensitizing capabilities, according ... the Journal of the American Medical Association . , ...
... Ulrich Stroeher, Chairman of the Advisory,Board of Berlin Heart, today ... the company on 30 September 2009. , ... one of the,intellectual fathers of the successful ventricular assist device ... this area as,coordinator for projects with external cooperation partners. He ...
... , ATLANTA, July 7 Crawford Canada,s Bill Johnstone ... Company,s (NYSE: CRDA ; CRDB) Global Technical ... designed to more effectively coordinate and grow this market-leading ... is a major differentiator for Crawford worldwide in the ...
... ... ... roving weather star, Al Roker, has packed up his Penske truck once again to hit ... consecutive year, "Lend a Hand" continues its mission to help small charities across the country ...
Cached Medicine News:Health News:MagnaCare Answers Need for New Prescription Drug Program 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2Health News:Fat-Cell Protein May Reduce Diabetes Risk 2Health News:Fat-Cell Protein May Reduce Diabetes Risk 3Health News:Berlin Heart Announces Restructuring of Management 2Health News:Bill Johnstone Named Senior Vice President of Crawford's Global Technical Services for the Americas 2Health News:Supergoop! Award-Winning SPF 30 Sunscreen & Skin Protection Lotion Featured On The Today Show 2
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the differential qualitative detection and quantitative determination of infectious mononucleosis and other heterophile antibodies in serum or plasma....
Color-enhanced hemagglutination slide test for the rapid qualitative and semi-quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: